{"id":42,"date":"2021-05-07T05:16:55","date_gmt":"2021-05-07T05:16:55","guid":{"rendered":"https:\/\/theempathycampaign.com\/index.php\/2021\/05\/07\/articles-the-empathy-campaign\/"},"modified":"2021-05-07T05:16:55","modified_gmt":"2021-05-07T05:16:55","slug":"articles-the-empathy-campaign","status":"publish","type":"post","link":"https:\/\/theempathycampaign.com\/index.php\/2021\/05\/07\/articles-the-empathy-campaign\/","title":{"rendered":"Articles \u2013 The Empathy Campaign"},"content":{"rendered":"

January 2015<\/strong><\/p>\n

Is hepatitis C subtyping still relevant in the era of direct-acting antiviral therapy?<\/a><\/h3>\n

Mohammed Eslam<\/a>,\u00a0Jacob George\u00a0<\/a>Pages 5-8<\/p>\n

How to achieve immune control in chronic hepatitis B?<\/a><\/h3>\n

Margo J. H. van Campenhout<\/a>,\u00a0Harry L. A. Janssen\u00a0<\/a>Pages 9-16<\/p>\n

Clinical significance of circulating miR-122 in patients with dual chronic hepatitis B and C virus infection<\/a><\/h3>\n

Huei-Ru Cheng<\/a>,\u00a0Jia-Horng Kao<\/a>,\u00a0Hui-Lin Wu<\/a>,\u00a0Tai-Chung Tseng<\/a>\u2026 Pages 35-42<\/p>\n

Reimbursement policies in the Asia-Pacific for chronic hepatitis B<\/a><\/h3>\n

Seng Gee Lim<\/a>,\u00a0Deepak N. Amarapurkar<\/a>,\u00a0Henry Lik-Yuen Chan<\/a>\u2026 Pages 43-51<\/p>\n

HCV genotype 1 subtypes (1a and 1b): similarities and differences in clinical features and therapeutic outcome<\/a><\/h3>\n

A comparative study of patients\u2019 knowledge about hepatitis C in the United States and in urban and rural China<\/a><\/h3>\n

Elizabeth Wu<\/a>,\u00a0Xisui Chen<\/a>,\u00a0Zhe Guan<\/a>,\u00a0Claudia Cao<\/a>,\u00a0Huiying Rao<\/a>\u2026 Pages 58-66<\/p>\n

Prognostic effect of response to interferon therapy after laparoscopic splenectomy among patients with marked thrombocytopenia and hepatitis C virus-related cirrhosis<\/a><\/h3>\n

Hideyuki Tamai<\/a>,\u00a0Yoshiyuki Mori<\/a>,\u00a0Naoki Shingaki<\/a>,\u00a0Ryo Shimizu<\/a>\u2026 Pages 67-75<\/p>\n

High sustained virological response to pegylated interferon and ribavirin for recurrent genotype 3 hepatitis C infection post-liver transplantation<\/a><\/h3>\n

Nabiha Faisal<\/a>,\u00a0Khalid Mumtaz<\/a>,\u00a0Max Marquez<\/a>,\u00a0Eberhard L. Renner<\/a>\u2026 Pages 76-83<\/p>\n

April 2015<\/strong><\/p>\n

Sofosbuvir for treatment of chronic hepatitis C<\/a><\/h3>\n

Sarah Kattakuzhy<\/a>,\u00a0Rachel Levy<\/a>,\u00a0Shyam Kottilil\u00a0<\/a>Pages 161-173<\/p>\n

Management of post transplant hepatitis C in the direct antiviral agents era<\/a><\/h3>\n

Audrey Coilly<\/a>,\u00a0Bruno Roche<\/a>,\u00a0Jean-Charles Duclos-Vall\u00e9e<\/a>\u2026 Pages 192-201<\/p>\n

Long-term use of methotrexate does not result in hepatitis B reactivation in rheumatologic patients<\/a><\/h3>\n

Charlie Laohapand<\/a>,\u00a0Emvalee Arromdee<\/a>,\u00a0Tawesak Tanwandee\u00a0\u00a0<\/a>Pages 202-208<\/p>\n

High rate of core promoter and precore mutations in patients with chronic hepatitis B<\/a><\/h3>\n

Sumbella F. Baqai<\/a>,\u00a0James Proudfoot<\/a>,\u00a0Debbie H. Yi<\/a>\u2026 Pages 209-217<\/p>\n

Preemptive adefovir versus lamivudine for prevention of hepatitis B reactivation in chronic hepatitis B patients undergoing chemotherapy<\/a><\/h3>\n

Edith Y. Ho<\/a>,\u00a0Thomas Yau<\/a>,\u00a0Franck Rousseau<\/a>,\u00a0E. Jenny Heathcote<\/a>\u2026 Pages 224-230<\/p>\n

Adipocytokines and liver fibrosis stages in patients with chronic hepatitis B virus infection<\/a><\/h3>\n

Ching-Sheng Hsu<\/a>,\u00a0Wei-Liang Liu<\/a>,\u00a0You-Chen Chao<\/a>\u2026 Pages 231-242<\/p>\n

Long-term clinical outcomes in cirrhotic chronic hepatitis B patients treated with tenofovir disoproxil fumarate for up to 5\u00a0years<\/a><\/h3>\n

Maria Buti<\/a>,\u00a0Scott Fung<\/a>,\u00a0Edward Gane<\/a>,\u00a0Nezam H. Afdhal<\/a>\u2026 Pages 243-250<\/p>\n

Influence of\u00a0IFNL3.rs12979860<\/em>\u00a0and\u00a0IFNL4.ss469415590<\/em>\u00a0polymorphism on clearance of hepatitis C virus infection among Egyptians<\/a><\/h3>\n

Susanne Knapp<\/a>,\u00a0Zainab Zakaria<\/a>,\u00a0Mohamed Hashem<\/a>,\u00a0Hassan Zaghla<\/a>\u2026<\/p>\n

July 2015<\/strong><\/p>\n

Anti-viral therapy in hepatitis B virus reactivation with acute-on-chronic liver failure<\/a><\/h3>\n

Man-Fung Yuen\u00a0<\/a>Pages 373-377<\/p>\n

A review of the burden of hepatitis C virus infection in China, Japan, South Korea and Taiwan<\/a><\/h3>\n

Heather Bennett<\/a>,\u00a0Nathalie Waser<\/a>,\u00a0Karissa Johnston<\/a>\u2026 Pages 378-390<\/p>\n

Acute kidney injury in hepatitis B-related acute-on-chronic liver failure without preexisting liver cirrhosis<\/a><\/h3>\n

Zuxiong Huang<\/a>,\u00a0Chun Lin<\/a>,\u00a0Jiankai Fang<\/a>,\u00a0Ning Wang<\/a>,\u00a0Rui Zhou<\/a>\u2026 Pages 416-423<\/p>\n

HCV NS5A resistance-associated variants in a group of real-world Japanese patients chronically infected with HCV genotype 1b<\/a><\/h3>\n

Yosuke Hirotsu<\/a>,\u00a0Tatsuo Kanda<\/a>,\u00a0Hiroshi Matsumura<\/a>\u2026 Pages 424-430<\/p>\n

Sustained virologic response to standard interferon or pegylated interferon and ribavirin in patients with hepatitis C virus genotype 5: systematic review and meta-analysis of ten studies and 423 patients<\/a><\/h3>\n

Pardha Devaki<\/a>,\u00a0David Jencks<\/a>,\u00a0Brittany E. Yee<\/a>,\u00a0Mindie H. Nguyen\u00a0\u00a0<\/a>Pages 431-437<\/p>\n

October 2015<\/strong><\/p>\n

Features of hepatitis C virus infection, current therapies and ongoing clinical trials in ten Asian Pacific countries<\/a><\/h3>\n

Masao Omata<\/a>,\u00a0Tatsuo Kanda<\/a>,\u00a0Osamu Yokosuka<\/a>,\u00a0Darrell Crawford<\/a>\u2026 Pages 486-507<\/p>\n

Response-guided therapy of regimens based on PEG-interferon for chronic hepatitis B using on-treatment hepatitis B surface antigen quantification: a meta-analysis<\/a><\/h3>\n

Hong Peng<\/a>,\u00a0Fang Wei<\/a>,\u00a0Jun-Ying Liu<\/a>,\u00a0Huai-Dong Hu<\/a>,\u00a0Hong Ren<\/a>\u2026 Pages 543-557<\/p>\n

Performance of transient elastography assessing fibrosis of single hepatitis B virus infection: a systematic review and meta-analysis of a diagnostic test<\/a><\/h3>\n

Xueying Xu<\/a>,\u00a0Yang Su<\/a>,\u00a0Ruixiang Song<\/a>,\u00a0Yang Sheng<\/a>,\u00a0Wensi Ai<\/a>\u2026 Pages 558-566<\/p>\n

Predicting clinical outcomes in patients with HBsAg-positive chronic hepatitis<\/a><\/h3>\n

Myron John Tong<\/a>,\u00a0Thatcher Thi Huynh<\/a>,\u00a0Surachate Siripongsakun<\/a>\u2026 Pages 567-577<\/p>\n

Interferon-\u03b1 plus ribavirin yields 98\u00a0% sustained virologic response in children aged 1\u20135\u00a0years with iatrogenic chronic hepatitis C<\/a><\/h3>\n

Shi-Shu Zhu<\/a>,\u00a0Qing-Lei Zeng<\/a>,\u00a0Yi Dong<\/a>,\u00a0Zhi-Qiang Xu<\/a>,\u00a0Li-Min Wang<\/a>\u2026 Pages 578-585<\/p>\n

Deregulation of microRNA expression in peripheral blood mononuclear cells from patients with HCV-related malignancies<\/a><\/h3>\n

Alessia Piluso<\/a>,\u00a0Laura Gragnani<\/a>,\u00a0Elisa Fognani<\/a>,\u00a0Elena Grandini<\/a>\u2026 Pages 586-593<\/p>\n

January 2016<\/strong><\/p>\n

Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update<\/a><\/h3>\n

K. Sarin<\/a>,\u00a0M. Kumar<\/a>,\u00a0G. K. Lau<\/a>,\u00a0Z. Abbas<\/a>,\u00a0H. L. Y. Chan<\/a>\u2026 Pages 1-98<\/p>\n

Looking into the crystal ball: biomarkers for outcomes of HBV infection<\/a><\/h3>\n

Hung-Chih Yang<\/a>,\u00a0Jia-Horng Kao\u00a0<\/a> Pages 99-101<\/p>\n

Need to improve awareness and management of hepatitis B reactivation in patients receiving immunosuppressive therapy<\/a><\/h3>\n

Man-Fung Yuen\u00a0\u00a0<\/a>Pages 102-105<\/p>\n

Late liver function test abnormalities post-adult liver transplantation: a review of the etiology, investigation, and management<\/a><\/h3>\n

Oscar Mitchell<\/a>,\u00a0Arif M. Cosar<\/a>,\u00a0Mohammad U. Malik<\/a>,\u00a0Ahmet Gurakar\u00a0<\/a> Pages 106-114<\/p>\n

Role of serum hepatitis B virus marker quantitation to differentiate natural history phases of HBV infection<\/a><\/h3>\n

Li Wang<\/a>,\u00a0Zhi-Qiang Zou<\/a>,\u00a0Kai Wang<\/a>,\u00a0Ji-Guang Yu<\/a>,\u00a0Xiang-Zhong Liu\u00a0<\/a> Pages 133-138<\/p>\n

Admissions for hepatitis B reactivation in patients receiving immunosuppressive therapy remain unchanged from 1999 to 2014<\/a><\/h3>\n

Arpan Patel<\/a>,\u00a0Suna Yapali<\/a>,\u00a0Anna S. F. Lok\u00a0<\/a>Pages 139-146\u00a0<\/p>\n

Aligning to the sample-specific reference sequence to optimize the accuracy of next-generation sequencing analysis for hepatitis B virus<\/a><\/h3>\n

Wen-Chun Liu<\/a>,\u00a0Chih-Peng Lin<\/a>,\u00a0Chun-Pei Cheng<\/a>,\u00a0Cheng-Hsun Ho<\/a>\u2026 Pages 147-157<\/p>\n

March 2016<\/strong><\/p>\n

Oral antiviral therapy reduces the risk of hepatocellular carcinoma in persons with chronic hepatitis B infection: combining evidence and common sense<\/a><\/h3>\n

Yuanyuan Kong<\/a>,\u00a0Hong You<\/a>,\u00a0Jidong Jia\u00a0<\/a>Pages 239-241<\/p>\n

Daclatasvir-containing all-oral regimens for the treatment of hepatitis C virus infection<\/a><\/h3>\n

Sheng-Shun Yang<\/a>,\u00a0Jia-Horng Kao<\/a>Pages 258-266<\/p>\n

Advances in therapeutics for chronic hepatitis B<\/a><\/h3>\n

Ninghan Yang<\/a>,\u00a0Antonio Bertoletti<\/a>Pages 277-285<\/p>\n

Efficacy and resistance to telbivudine treatment in chronic hepatitis B patients with favorable predictors: a multicenter study in Taiwan<\/a><\/h3>\n

Chia-Chi Wang<\/a>,\u00a0Chih-Lin Lin<\/a>,\u00a0Tsai-Yuan Hsieh<\/a>,\u00a0Kuo-Chih Tseng<\/a>\u2026 Pages 294-301<\/p>\n

Tenofovir rescue therapy in chronic hepatitis B patients who failed previous nucleoside analogue treatment<\/a><\/h3>\n

Dorota Kozielewicz<\/a>,\u00a0Waldemar Halota<\/a>,\u00a0Magdalena Wietlicka-Piszcz\u00a0<\/a>Pages 302-309<\/p>\n

High adherence to all-oral directly acting antiviral HCV therapy among an inner-city patient population in a phase 2a study<\/a><\/h3>\n

Tess Petersen<\/a>,\u00a0Kerry Townsend<\/a>,\u00a0Lori A. Gordon<\/a>\u2026Pages 310-319<\/p>\n

Effects of long-term entecavir treatment on the incidence of hepatocellular carcinoma in chronic hepatitis B patients<\/a><\/h3>\n

Takao Watanabe<\/a>,\u00a0Yoshio Tokumoto<\/a>,\u00a0Kouji Joko<\/a>,\u00a0Kojiro Michitaka<\/a>\u2026Pages 320-327<\/p>\n

May 2016<\/strong><\/p>\n

https:\/\/link.springer.com\/journal\/12072\/10\/3<\/a><\/p>\n

Prevention and management of hepatitis B virus reactivation in cancer patients<\/a><\/h3>\n

Ka-Shing Cheung<\/a>,\u00a0Wai-Kay Seto<\/a>,\u00a0Ching-Lung Lai<\/a>,\u00a0Man-Fung Yuen<\/a>Pages 407-414<\/p>\n

Hepatitis C virus as a systemic disease: reaching beyond the liver<\/a><\/h3>\n

Kirat Gill<\/a>,\u00a0Hasmik Ghazinian<\/a>,\u00a0Richard Manch<\/a>,\u00a0Robert Gish<\/a>Pages 415-423<\/p>\n

Advances in the management of HIV\/HCV coinfection<\/a><\/h3>\n

Mattias Mandorfer<\/a>,\u00a0Philipp Schwabl<\/a>,\u00a0Sebastian Steiner<\/a>\u2026Pages 424-435<\/p>\n

The effect of plasma exchange on entecavir-treated chronic hepatitis B patients with hepatic de-compensation and acute-on-chronic liver failure<\/a><\/h3>\n

Wan Yue-Meng<\/a>,\u00a0Li-Hong Yang<\/a>,\u00a0Jin-Hui Yang<\/a>,\u00a0Ying Xu<\/a>,\u00a0Jing Yang<\/a>\u2026Pages 462-469<\/p>\n

Males seropositive for hepatitis B surface antigen are at risk of lower bone mineral density: the 2008\u20132010 Korea National Health and Nutrition Examination Surveys<\/a><\/h3>\n

Myong Ki Baeg<\/a>,\u00a0Seung Kew Yoon<\/a>,\u00a0Sun-Hye Ko<\/a>,\u00a0Kyung-Do Han<\/a>\u2026Pages 470-477<\/p>\n

Ritonavir-boosted danoprevir-based regimens in treatment-naive and prior null responders with HCV genotype 1 or 4 and compensated cirrhosis<\/a><\/h3>\n

Edward J. Gane<\/a>,\u00a0R\u00e9gine Rouzier<\/a>,\u00a0Tarek Hassanein<\/a>\u2026Pages 478-487<\/p>\n

July 2016<\/strong><\/p>\n

iNKT cells in chronic HBV: a balancing act<\/a><\/h3>\n

Maike Hofmann<\/a>,\u00a0Robert Thimme<\/a>Pages 535-537<\/p>\n

HBV culture and infectious systems<\/a><\/h3>\n

Nelson Hayes<\/a>,\u00a0Kazuaki Chayama<\/a>Pages 559-566<\/p>\n

Hepatitis B virus receptors and molecular drug targets<\/a><\/h3>\n

Eloi R. Verrier<\/a>,\u00a0Che C. Colpitts<\/a>,\u00a0Camille Sureau<\/a>\u2026Pages 567-573<\/p>\n

Prevention of hepatitis B virus-associated liver diseases by antiviral therapy<\/a><\/h3>\n

Akinobu Tawada<\/a>,\u00a0Tatsuo Kanda<\/a>,\u00a0Fumio Imazeki<\/a>,\u00a0Osamu Yokosuka<\/a>Pages 574-593<\/p>\n

The dynamic changes of circulating invariant natural killer T cells during chronic hepatitis B virus infection<\/a><\/h3>\n

Man Li<\/a>,\u00a0Zhen-Hua Zhou<\/a>,\u00a0Xue-Hua Sun<\/a>,\u00a0Xin Zhang<\/a>,\u00a0Xiao-Jun Zhu<\/a>\u2026Pages 594-601<\/p>\n

Will a second biopsy sample affect treatment decisions in patients with chronic hepatitis B?<\/a><\/h3>\n

Fuat Ekiz<\/a>,\u00a0\u0130lhami Yuksel<\/a>,\u00a0Ata Turker Arik\u00f6k<\/a>,\u00a0Baris Yilmaz<\/a>\u2026Pages 602-605<\/p>\n

Association between hepatitis B virus basal core promoter\/precore region mutations and the risk of hepatitis B-related acute-on-chronic liver failure in the Chinese population: an updated meta-analysis<\/a><\/h3>\n

Xueyuan Nian<\/a>,\u00a0Zhihui Xu<\/a>,\u00a0Yan Liu<\/a>,\u00a0Jianhong Chen<\/a>,\u00a0Xiaodong Li<\/a>\u2026Pages 606-615<\/p>\n

Examining the clinical course of genotype 1 chronic hepatitis C patients treated with the cosmos regimen: including patients with advanced liver disease and East Asian ancestry<\/a><\/h3>\n

Marina Roytman<\/a>,\u00a0Resham Ramkissoon<\/a>,\u00a0Christina Wu<\/a>,\u00a0Leena Hong<\/a>\u2026Pages 616-623<\/p>\n

Is response guided therapy dead? Low cure rates in patients with detectable hepatitis C virus at week 4 of treatment<\/a><\/h3>\n

Karla Thornton<\/a>,\u00a0Paulina Deming<\/a>,\u00a0Richard A. Manch<\/a>,\u00a0Ann Moore<\/a>\u2026Pages 624-631<\/p>\n

September 2016<\/strong><\/p>\n

APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing<\/a><\/h3>\n

Masao Omata<\/a>,\u00a0Tatsuo Kanda<\/a>,\u00a0Lai Wei<\/a>,\u00a0Ming-Lung Yu<\/a>\u2026Pages 681-701<\/p>\n

APASL consensus statements and recommendation on treatment of hepatitis C<\/a><\/h3>\n

Masao Omata<\/a>,\u00a0Tatsuo Kanda<\/a>,\u00a0Lai Wei<\/a>,\u00a0Ming-Lung Yu<\/a>\u2026Pages 702-726<\/p>\n

HBsAg loss in chronic hepatitis B: pointers to the benefits of curative therapy<\/a><\/h3>\n

Geoffrey Dusheiko<\/a>,\u00a0Bo Wang<\/a>,\u00a0Ivana Carey<\/a>Pages 727-729<\/p>\n

Hepatitis C virus cell entry: a target for novel antiviral strategies to address limitations of direct acting antivirals<\/a><\/h3>\n

Che C. Colpitts<\/a>,\u00a0Thomas F. Baumert<\/a>Pages 741-748<\/p>\n

Management of post liver transplantation recurrent hepatitis C infection with directly acting antiviral drugs: a review<\/a><\/h3>\n

Dinesh Jothimani<\/a>,\u00a0Sanjay Govil<\/a>,\u00a0Mohamed Rela<\/a>Pages 749-761<\/p>\n

Entecavir plus tenofovir combination therapy for chronic hepatitis B in patients with previous nucleos(t)ide treatment failure<\/a><\/h3>\n

Fabien Zoulim<\/a>,\u00a0Jolanta Bia\u0142kowska-Warzecha<\/a>\u2026Pages 779-788<\/p>\n

Twelve-week ribavirin-free direct-acting antivirals for treatment-experienced Chinese with HCV genotype 1b infection including cirrhotic patients<\/a><\/h3>\n

Dong Ji<\/a>,\u00a0Guo-Feng Chen<\/a>,\u00a0Cheng Wang<\/a>,\u00a0Yu-Dong Wang<\/a>,\u00a0Qing Shao<\/a>\u2026Pages 789-798<\/p>\n

HBsAg loss in a New Zealand community study with 28-year follow-up: rates, predictors and long-term outcomes<\/a><\/h3>\n

Tien Huey Lim<\/a>,\u00a0Edward Gane<\/a>,\u00a0Chris Moyes<\/a>,\u00a0Barry Borman<\/a>\u2026Pages 829-837<\/p>\n

November 2016<\/strong><\/p>\n

Hepatitis B virus genotypes: epidemiological and clinical relevance in Asia<\/a><\/h3>\n

Qiuju Tian<\/a>,\u00a0Jidong Jia<\/a>Pages 854-860<\/p>\n

Hepatitis C genotype 3 disease<\/a><\/h3>\n

Sarah Kattakuzhy<\/a>,\u00a0Rachel Levy<\/a>,\u00a0Elana Rosenthal<\/a>,\u00a0Lydia Tang<\/a>\u2026 Pages 861-870<\/p>\n

Functionally aberrant dendritic cell subsets and expression of DC-SIGN differentiate acute from chronic HBV infection<\/a><\/h3>\n

Sukriti Sukriti<\/a>,\u00a0Nirupma Trehanpati<\/a>,\u00a0Manoj Kumar<\/a>\u2026 Pages 916-923<\/p>\n

Cost-effectiveness analysis of tenofovir disoproxil fumarate for treatment of chronic hepatitis B in China<\/a><\/h3>\n

Weixia Ke<\/a>,\u00a0Chi Zhang<\/a>,\u00a0Li Liu<\/a>,\u00a0Yanhui Gao<\/a>,\u00a0Zhenjiang Yao<\/a>\u2026 Pages 924-936<\/p>\n

Elevated hepatic lipid and interferon stimulated gene expression in HCV GT3 patients relative to non-alcoholic steatohepatitis<\/a><\/h3>\n

Shikha Shrivastava<\/a>,\u00a0Eric G. Meissner<\/a>,\u00a0Emily Funk<\/a>,\u00a0Seerat Poonia<\/a>\u2026 Pages 937-946<\/p>\n

A phase IIIb study of ledipasvir\/sofosbuvir fixed-dose combination tablet in treatment-na\u00efve and treatment-experienced Korean patients chronically infected with genotype 1 hepatitis C virus<\/a><\/h3>\n

Young-Suk Lim<\/a>,\u00a0Sang Hoon Ahn<\/a>,\u00a0Kwan Sik Lee<\/a>,\u00a0Seung Woon Paik<\/a>\u2026Pages 947-955<\/p>\n

Serial measurement of\u00a0Wisteria floribunda agglutinin<\/em>\u00a0positive Mac-2-binding protein is useful for predicting liver fibrosis and the development of hepatocellular carcinoma in chronic hepatitis C patients treated with IFN-based and IFN-free therapy<\/a><\/h3>\n

Hiroko Nagata<\/a>,\u00a0Mina Nakagawa<\/a>,\u00a0Yuki Nishimura-Sakurai<\/a>,\u00a0Yu Asano<\/a>\u2026Pages 956-964<\/p>\n

Correlates of disease-specific knowledge among patients with chronic hepatitis B or hepatitis C infection in India<\/a><\/h3>\n

Aracely Tamayo<\/a>,\u00a0Samir R. Shah<\/a>,\u00a0Shobna Bhatia<\/a>,\u00a0Abhijit Chowdhury<\/a>\u2026<\/p>\n

Jan 2017<\/strong><\/p>\n

Hepatitis B reactivation in patients receiving immunosuppressive therapy: a hidden menace<\/a><\/h3>\n

Chih-Lin Lin<\/a>,\u00a0Jia-Horng Kao<\/a><\/p>\n

Interferon-free treatment for HCV-infected patients with decompensated cirrhosis<\/a><\/h3>\n

Tatsuo Kanda<\/a><\/p>\n

Molecular mechanisms of HBeAg in persistent HBV infection<\/a><\/h3>\n

Li-Min Chen<\/a>,\u00a0Xue-Gong Fan<\/a>,\u00a0Jing Ma<\/a>,\u00a0Bo He<\/a>,\u00a0Yong-Fang Jiang<\/a><\/p>\n

HBV reactivation risk factors in patients with chronic HBV infection with low replicative state and resolved HBV infection undergoing hematopoietic stem cell transplantation in Korea<\/a><\/h3>\n

Chung Hwan Jun<\/a>,\u00a0Ban Suk Kim<\/a>,\u00a0Chan Young Oak<\/a>,\u00a0Du Hyeon Lee<\/a><\/p>\n

Hepatitis B virus infection in children of HBV-related chronic liver disease patients: a study of intra-familial HBV transmission<\/a><\/h3>\n

Hartono Gunardi<\/a>,\u00a0Melanie Y. Iskandar<\/a>,\u00a0Turyadi<\/a>,\u00a0Susan I. Ie<\/a><\/p>\n

March 2017<\/strong><\/p>\n

Elbasvir\/grazoprevir for treatment of chronic hepatitis C virus infection<\/a><\/h3>\n

Chandana Papudesu<\/a>,\u00a0Shyamasundaran Kottilil<\/a>,\u00a0Shashwatee Ba<\/a><\/p>\n

Sofosbuvir\/velpatasvir: a pangenotypic drug to simplify HCV therapy<\/a><\/h3>\n

Rebecca Lee<\/a>,\u00a0Shyam Kottilil<\/a>,\u00a0Eleanor Wilson<\/a><\/p>\n

Virus-induced hepatocellular carcinoma with special emphasis on HBV<\/a><\/h3>\n

Ming Wang<\/a>,\u00a0Dong Xi<\/a>,\u00a0Qin Ning<\/a><\/p>\n

Efficacy and safety of daclatasvir plus pegylated-interferon alfa 2a and ribavirin in previously untreated HCV subjects coinfected with HIV and HCV genotype-1: a Phase III, open-label study<\/a><\/h3>\n

Mark S. Sulkowski<\/a>,\u00a0Walford J. Fessel<\/a>,\u00a0Adriano Lazzarin<\/a>\u2026<\/p>\n

May 2017<\/strong><\/p>\n

HCV management in resource-constrained countries<\/a><\/h3>\n

Seng Gee Lim<\/a><\/p>\n

Subcirrhotic liver stiffness by FibroScan correlates with lower risk of hepatocellular carcinoma in patients with HBV-related cirrhosis<\/a><\/h3>\n

Mi Young Jeon<\/a>,\u00a0Hye Won Lee<\/a>,\u00a0Seung Up Kim<\/a>,\u00a0Ja Yoon Heo<\/a><\/p>\n

Treatment of chronic hepatitis C genotype 3 with Sofosbuvir-based therpy: a real-life study<\/a><\/h3>\n

Sandeep Singh Sidhu<\/a>,\u00a0Nirmaljeet Singh Malhi<\/a>,\u00a0Omesh Goya<\/a><\/p>\n

A simple bedside blood test (Fibrofast; FIB-5) is superior to FIB-4 index for the differentiation between non-significant and significant fibrosis in patients with chronic hepatitis C<\/a><\/h3>\n
    \n
  1. Shiha<\/a>,\u00a0S. Seif<\/a>,\u00a0A. Eldesoky<\/a>,\u00a0M. Elbasiony<\/a>,\u00a0R. Soliman<\/a>\u2026<\/li>\n<\/ol>\n

    July 2017<\/strong><\/p>\n

    Current progress in host innate and adaptive immunity against hepatitis C virus infection<\/a><\/h3>\n

    Jijing Shi<\/a>,\u00a0Yuanyuan Li<\/a>,\u00a0Wenxian Chang<\/a>,\u00a0Xuexiu Zhang<\/a>\u2026<\/p>\n

    Safety, pharmacokinetics and pharmacogenetics of a single ascending dose of pradefovir, a novel liver-targeting, anti-hepatitis B virus drug, in healthy Chinese subjects<\/a><\/h3>\n

    Yanhua Ding<\/a>,\u00a0Hong Zhang<\/a>,\u00a0Xiaojiao Li<\/a>,\u00a0Cuiyun Li<\/a>,\u00a0Guiling Chen<\/a><\/p>\n

    Noninvasive serum models to predict significant liver related events in chronic hepatitis C<\/a><\/h3>\n

    Ragesh Babu Thandassery<\/a>,\u00a0Saad Al Kaabi<\/a>,\u00a0Madiha E. Soofi<\/a>\u2026<\/p>\n

    September 2017<\/strong><\/p>\n

    Functional restoration of CD56bright<\/sup>\u00a0NK cells facilitates immune control via IL-15 and NKG2D in patients under antiviral treatment for chronic hepatitis B<\/a><\/h3>\n

    Tao Chen<\/a>,\u00a0Lin Zhu<\/a>,\u00a0Aichao Shi<\/a>,\u00a0Lin Ding<\/a>,\u00a0Xiaoping Zhang<\/a><\/p>\n

    Risk of hepatitis B reactivation in HBsAg-negative\/HBcAb-positive patients with undetectable serum HBV DNA after treatment with rituximab for lymphoma: a meta-analysis<\/a><\/h3>\n

    Zilin Tang<\/a>,\u00a0Xiaodong Li<\/a>,\u00a0Shunquan Wu<\/a>,\u00a0Yan Liu<\/a>,\u00a0Yan Qiao<\/a>\u2026<\/p>\n

    Ledipasvir\/sofosbuvir without ribavirin is effective in the treatment of recurrent hepatitis C virus infection post-liver transplant<\/a><\/h3>\n

    Mohamed Shoreibah<\/a>,\u00a0Jordan Orr<\/a>,\u00a0DeAnn Jones<\/a>,\u00a0Jie Zhang<\/a><\/p>\n

    A cinnamon-derived procyanidin type A compound inhibits hepatitis C virus cell entry<\/a><\/h3>\n

    Catherine Fauvelle<\/a>,\u00a0Melanie Lambotin<\/a>,\u00a0Laura Heydmann<\/a>\u2026<\/p>\n

    November 2017<\/strong><\/p>\n

    Viral factors for HBV mother-to-child transmission<\/a><\/h3>\n

    James S. Park<\/a>,\u00a0Calvin Q. Pan<\/a><\/p>\n

    Mother-to-infant transmission of hepatitis B virus: challenges and perspectives<\/a><\/h3>\n

    Yi-Fen Shih<\/a>,\u00a0Chun-Jen Liu<\/a><\/p>\n

    Hepatitis B virus: virology, molecular biology, life cycle and intrahepatic spread<\/a><\/h3>\n

    Scenarios to manage the hepatitis C disease burden and associated economic impact of treatment in Turkey<\/a><\/h3>\n

    Necati \u00d6rmeci<\/a>,\u00a0Simten Malhan<\/a>,\u00a0\u0130smail Bal\u0131k<\/a>,\u00a0G\u00fcl Erg\u00f6r<\/a>\u2026<\/p>\n

    January 2018<\/strong><\/p>\n

    Autoantibody to apolipoprotein A-1 in hepatitis C virus infection: a role in atherosclerosis?<\/a><\/h3>\n

    Simon H. Bridge<\/a>,\u00a0Sabrina Pagano<\/a>,\u00a0Meleri Jones<\/a>,\u00a0Graham R. Foster<\/a><\/p>\n

    March 2018<\/strong><\/p>\n

    Prevention of mother-to-child transmission: the key of hepatitis B virus elimination<\/a><\/h3>\n

    Chih-Lin Lin<\/a>,\u00a0Jia-Horng Kao<\/a><\/p>\n

    The preS deletion of hepatitis B virus (HBV) is associated with liver fibrosis progression in patients with chronic HBV infection<\/a><\/h3>\n

    Fan Li<\/a>,\u00a0Xiaodong Li<\/a>,\u00a0Tao Yan<\/a>,\u00a0Yan Liu<\/a>,\u00a0Yongqian Cheng<\/a>\u2026<\/p>\n

    Safety and efficacy of lamivudine or telbivudine started in early pregnancy for mothers with active chronic hepatitis B<\/a><\/h3>\n

    Tianyu He<\/a>,\u00a0Yuqing Bai<\/a>,\u00a0Haodong Cai<\/a>,\u00a0Xiaojuan Ou<\/a>,\u00a0Min Liu<\/a><\/p>\n

    Ledipasvir\/sofosbuvir for treatment-naive and treatment-experienced Chinese patients with genotype 1 HCV: an open-label, phase 3b study<\/a><\/h3>\n

    Lai Wei<\/a>,\u00a0Qing Xie<\/a>,\u00a0Jin Lin Hou<\/a>,\u00a0Hong Tang<\/a>,\u00a0Qin Ning<\/a>,\u00a0Jun Cheng<\/a>\u2026<\/p>\n

    Efficacy and safety of ledipasvir\/sofosbuvir for genotype 1b chronic hepatitis C patients with moderate renal impairment<\/a><\/h3>\n

    Tomomi Okubo<\/a>,\u00a0Masanori Atsukawa<\/a>,\u00a0Akihito Tsubota<\/a>\u2026<\/p>\n

    High prevalence of HCV (GT4)-related TSH abnormality among 13402 Egyptian patients treated with direct acting antiviral therapy<\/a><\/h3>\n

    Rasha Eletreby<\/a>,\u00a0Mohamed Said<\/a>,\u00a0Zeinab Abdellatif<\/a>,\u00a0Yasmin Saad<\/a><\/p>\n

    Effect of achieving sustained virological response before hepatitis C virus-related hepatocellular carcinoma occurrence on survival and recurrence after curative surgical microwave ablation<\/a><\/h3>\n

    Tomoki Ryu<\/a>,\u00a0Yuko Takami<\/a>,\u00a0Yoshiyuki Wada<\/a>,\u00a0Masaki Tateishi<\/a>\u2026<\/p>\n

    May 2018<\/strong><\/p>\n

    Glecaprevir\/pibrentasvir expands reach while reducing cost and duration of hepatitis C virus therapy<\/a><\/h3>\n

    Ameer Abutaleb<\/a>,\u00a0Shyam Kottilil<\/a>,\u00a0Eleanor Wilson<\/a><\/p>\n

    Platelets\u2019 increase is associated with improvement of liver fibrosis in entecavir-treated chronic hepatitis B patients with significant liver fibrosis<\/a><\/h3>\n

    Lin Wang<\/a>,\u00a0Bingqiong Wang<\/a>,\u00a0Hong You<\/a>,\u00a0Xiaoning Wu<\/a>,\u00a0Jialing Zhou<\/a>\u2026<\/p>\n

    Safety and effectiveness of daclatasvir and asunaprevir dual therapy in patients with genotype 1 chronic hepatitis C: results from postmarketing surveillance in Japan<\/a><\/h3>\n

    Fumitaka Suzuki<\/a>,\u00a0Naoya Hatanaka<\/a>,\u00a0Etsuya Bando<\/a>,\u00a0Koji Nakamura<\/a><\/p>\n

    July 2018<\/strong><\/p>\n

    Hepatitis C virus genotype 4-infection and interferon-free treatment in Egypt<\/a><\/h3>\n

    Tatsuo Kanda<\/a>,\u00a0Shunichi Matsuoka<\/a>,\u00a0Mitsuhiko Moriyama<\/a><\/p>\n

    Depression, fatigue and neurocognitive deficits in chronic hepatitis C<\/a><\/h3>\n

    Sern Wei Yeoh<\/a>,\u00a0Alex C. N. Holmes<\/a>,\u00a0Michael M. Saling<\/a>\u2026<\/p>\n

    Global HBV burden: guesstimates and facts<\/a><\/h3>\n

    Dina Ginzberg<\/a>,\u00a0Robert J. Wong<\/a>,\u00a0Robert Gish<\/a>Pages 315-329\u00a0<\/em><\/strong><\/p>\n

    Impact of viral hepatitis B status on outcomes of intrahepatic cholangiocarcinoma: a meta-analysis<\/a><\/h3>\n

    Seogsong Jeong<\/a>,\u00a0Guijuan Luo<\/a>,\u00a0Zhi-Heng Wang<\/a>,\u00a0Meng Sha<\/a>,\u00a0Lei Chen<\/a>\u2026Pages 330-338\u00a0<\/em><\/strong><\/p>\n

    Sofosbuvir plus Daclatasvir with or without ribavirin for treatment of chronic HCV genotype 4 patients: real-life experience<\/a><\/h3>\n

    Shiha<\/a>,\u00a0R. Soliman<\/a>,\u00a0M. ElBasiony<\/a>,\u00a0A. A. Hassan<\/a>\u2026 Pages 339-347\u00a0<\/em><\/strong><\/p>\n

    Efficacy and safety of sofosbuvir plus daclatasvir with or without ribavirin: large real-life results of patients with chronic hepatitis C genotype 4<\/a><\/h3>\n

    Adel Abdel-Moneim<\/a>,\u00a0Alaa Aboud<\/a>,\u00a0Mohamed Abdel-Gabaar<\/a>\u2026 Pages 348-355<\/p>\n

    Sofosbuvir\u2013velpatasvir plus ribavirin in Japanese patients with genotype 1 or 2 hepatitis C who failed direct-acting antivirals<\/a><\/h3>\n

    Namiki Izumi<\/a>,\u00a0Tetsuo Takehara<\/a>,\u00a0Kazuaki Chayama<\/a>\u2026 Pages 356-367<\/p>\n

    September 2018<\/strong><\/p>\n

    Fatty liver checkmates hepatitis B virus<\/a><\/h3>\n

    Gayatri Ramakrishna<\/a>,\u00a0Nirupma Trehanpati\u00a0\u00a0<\/a>Pages 387-389\u00a0<\/em><\/strong><\/p>\n

    Clinical implication and viral mutation in basal core promoter\/pre-core of hepatitis B virus C\/D recombinant<\/a><\/h3>\n

    Hua Li<\/a>,\u00a0Qilu She<\/a>,\u00a0Yu Liu<\/a>,\u00a0Yuehe Ding<\/a>,\u00a0Shenghua Shi<\/a>,\u00a0Jijie Li<\/a>\u2026 Pages 447-455\u00a0<\/em><\/strong><\/p>\n

    Multiple doses of hepatitis B recombinant vaccine for chronic hepatitis B patients with low surface antigen levels: a pilot study<\/a><\/h3>\n

    Ming-Wei Lai<\/a>,\u00a0Chao-Wei Hsu<\/a>,\u00a0Chih-Lang Lin<\/a>,\u00a0Rong-Nan Chien<\/a>\u2026 Pages 456-464\u00a0<\/em><\/strong><\/p>\n

    \u00a0Tolerable and curable treatment in HIV\/HCV co-infected patients using anti-HCV direct antiviral agents: a real-world observation in China<\/a><\/h3>\n

    Yuanyuan Li<\/a>,\u00a0Linghua Li<\/a>,\u00a0Jun Liu<\/a>,\u00a0Da-Wei Zhang<\/a>,\u00a0Fang Zhao<\/a>\u2026 Pages 465-473<\/p>\n

    A changing paradigm: management and treatment of the HCV\/HIV-co-infected patient<\/a><\/h3>\n

    Ameer Abutaleb<\/a>,\u00a0Kenneth E. Sherman<\/a>Pages 500-509<\/p>\n

    Hepatitis B-positive health-care workers: why they should not switch to non-exposure-prone jobs<\/a><\/h3>\n

    Ankur Jindal\u00a0<\/a>Pages 520-522<\/p>","protected":false},"excerpt":{"rendered":"January 2015 Is hepatitis C subtyping still relevant in the era of direct-acting antiviral therapy? Mohammed Eslam,\u00a0Jacob George\u00a0Pages 5-8 How to achieve immune control in chronic hepatitis B? Margo J. H. van Campenhout,\u00a0Harry L. A. Janssen\u00a0Pages 9-16 Clinical significance of circulating miR-122 in patients with dual chronic hepatitis B and C virus infection Huei-Ru Cheng,\u00a0Jia-Horng […]","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-42","post","type-post","status-publish","format-standard","hentry","category-blog"],"_links":{"self":[{"href":"https:\/\/theempathycampaign.com\/index.php\/wp-json\/wp\/v2\/posts\/42","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/theempathycampaign.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/theempathycampaign.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/theempathycampaign.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/theempathycampaign.com\/index.php\/wp-json\/wp\/v2\/comments?post=42"}],"version-history":[{"count":0,"href":"https:\/\/theempathycampaign.com\/index.php\/wp-json\/wp\/v2\/posts\/42\/revisions"}],"wp:attachment":[{"href":"https:\/\/theempathycampaign.com\/index.php\/wp-json\/wp\/v2\/media?parent=42"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/theempathycampaign.com\/index.php\/wp-json\/wp\/v2\/categories?post=42"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/theempathycampaign.com\/index.php\/wp-json\/wp\/v2\/tags?post=42"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}